Cervical Cancer

>

Latest News

Pembrolizumab Combo Receives Canadian Approval in Cervical Cancer
Pembrolizumab Combo Receives Canadian Approval in Cervical Cancer

July 23rd 2025

Data from the phase 3 KEYNOTE-A18 trial support the approval of the pembrolizumab-based regimen for those with stage III to IVA cervical cancer in Canada.

More than 80% of patients who were screened for cervical cancer and provided with a self-collection kit did so by utilizing the kit.
Self-Collection May Help Increase Cervical Cancer Screening Rates

June 14th 2025

ctDNA Analysis Shows Durvalumab/CRT Reduced Progression in Advanced Cervical Cancer
ctDNA Analysis Shows Durvalumab/CRT Reduced Progression in Advanced Cervical Cancer

June 5th 2025

Data from KEYNOTE-A18 support pembrolizumab plus concurrent chemoradiotherapy as a standard of care in this cervical cancer population.
Pembrolizumab/Chemoradiation Prolongs Survival in Advanced Cervical Cancer

June 2nd 2025

Less radical surgery did not come at the expense of postoperative metrics, including 30-day readmissions, surgical findings, or receipt of adjuvant therapy.
Simple vs Radical Hysterectomy Shows Comparable Survival in Cervical Cancer

May 27th 2025

More News